Drug Overview 2018: Invega Sustenna/Invega Trinza (Paliperidone Palmitate; Johnson & Johnson) - ResearchAndMarkets.com

The "Drug Overview: Invega Sustenna/Invega Trinza" report has been added to ResearchAndMarkets.com's offering.



Invega Sustenna and Invega Trinza (paliperidone palmitate; Johnson & Johnson) are long-acting injectable formulations developed by Johnson & Johnson, using with Alkermes's technology.



The drugs contain paliperidone, a metabolite of the atypical antipsychotic Risperdal (risperidone; Johnson & Johnson). Similarly to Risperdal, Invega Sustenna and Invega Trinza block the dopamine receptors D2 and the serotonin receptors 5-HT2A, helping to alleviate schizophrenia symptoms.



In the US, Invega Sustenna was approved for treatment of schizophrenia in July 2009, and for the treatment of schizoaffective disorder in November 2014. In the EU and Japan, Invega Sustenna is marketed under the brand name Xeplion. It was approved in March 2011 in Europe, and in Japan in September 2013. The three-month formulation Invega Trinza was first approved in the US in May 2015, and in the EU in May 2016. Johnson & Johnson retains all marketing rights to the franchise across the US, Japan, and EU.



Key Topics Covered

1. Drug Overview
2. Product Profiles
3. Invega Sustenna/Invega Trinza: Schizophrenia

List of Figures

Figure 1: Invega Sustenna/Invega Trinza for schizophrenia - SWOT analysis

Figure 2: Drug assessment summary of Invega Sustenna/Invega Trinza for schizophrenia

Figure 3: Drug assessment summary of Invega Sustenna/Invega Trinza for schizophrenia

Figure 4: Invega Sustenna sales for schizophrenia across the US, Japan, and five major EU markets, by country, 2017-26

Figure 5: Invega Trinza sales for schizophrenia across the US and five major EU markets, by country, 2017-26



List of Tables

Table 1: Invega Sustenna/Invega Trinza drug profile

Table 2: Invega Sustenna pivotal trial data in schizophrenia

Table 3: Invega Trinza pivotal trial data in schizophrenia

Table 4: Invega Sustenna sales for schizophrenia across the US, Japan, and five major EU markets, by country M, 2017-26

Table 5: Invega Trinza sales for schizophrenia across the US and five major EU markets, by country M, 2017-26



For more information about this report visit https://www.researchandmarkets.com/research/n9px48/drug_overview?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20180523006605/en/